RODES Inc. and Ligand Pharmaceuticals Incorporated have signed a exclusive global license and supply agreements for three Captisol-enabled, or CE, programs. Under the terms of the agreements, for each program Ligand will be eligible to receive development and commercial milestone payments, revenue from the sales of Captisol, and royalties of 8% to 11% on future net sales. RODES will be responsible for all costs related to the development and commercialization of the programs. The three programs are: IM/IV CE Meloxicam for patients with acute pain, potentially delaying the use of opioids with associated risk of addiction; IM/IV CE Fosphenytoin to benefit patients with seizures, expanding the market to room-temperature access in all settings; and IN CE Budesonide + Azelastine fixed-dose combination to improve convenience and outcomes for patients with allergic rhinitis.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
101.1 USD | +2.14% |
|
+4.95% | +41.51% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+41.51% | 1.78B | |
+55.35% | 848B | |
+31.64% | 627B | |
-0.10% | 363B | |
+15.47% | 318B | |
+13.10% | 299B | |
+15.51% | 243B | |
+16.72% | 225B | |
+16.54% | 179B | |
+4.31% | 167B |
- Stock Market
- Equities
- LGND Stock
- News Ligand Pharmaceuticals Incorporated
- RODES Inc. and Ligand Pharmaceuticals Incorporated Sign License and Supply Agreements